Aug 2026· Neuropsychopharmacology Reports· Vol 46· 0 citations· 12 references
Medicine
TL;DR
Clinicians should consider the possibility of comorbid MS in patients with treatment‐resistant schizophrenia, particularly when atypical clinical or neurological features are present.
Abstract
Multiple sclerosis (MS) can present with neurological and psychiatric symptoms that may overlap with those of schizophrenia, making differentiation difficult particularly because their typical onset ages are similar. We present the case of a woman in her 50s who developed persecutory delusions and a subjective sense of being under surveillance in Year X‐31 and was diagnosed with schizophrenia. Despite the long‐term antipsychotic treatment, the patient's symptoms persisted and worsened. In Year X‐1, brain magnetic resonance imaging revealed multiple white matter lesions, and then cerebrospinal fluid analysis revealed oligoclonal bands, leading to a diagnosis of MS. Treatment with ofatumumab was initiated. Owing to persistent psychiatric symptoms, clozapine was administered, which showed partial effectiveness. This case highlights the clinical overlap between schizophrenia and MS and suggests that comorbid MS pathology may be clinically relevant in the context of treatment resistance and cognitive impairment. Similarities in symptoms and disease course raise the possibility that a subset of patients with schizophrenia may share pathophysiological features with MS. In addition, postmortem studies, including our previous and current observations, provide hypothesis‐generating support for partially overlapping MS‐like changes in some patients with schizophrenia. Clinicians should consider the possibility of comorbid MS in patients with treatment‐resistant schizophrenia, particularly when atypical clinical or neurological features are present.
The diagnostic challenge at the LOS/very-late-onset schizophrenia-like psychosis (VLOSLP) boundary is illustrated and it is emphasized that favorable functional outcomes are achievable in late-onset schizophrenia with appropriate multidisciplinary management and pharmacological adherence.
G. Mano, T. Perissotto, G. Scandiuzzi et al.· Brazilian Journal of Case Re...· 0 citations
Psychosis in Parkinson's disease (PD) is a common and debilitating non-motor symptom that can occur at any stage of the disease. PD psychosis (PDP) manifests as a diverse clinical spectrum that can include misperceptions, passage and presence phenomena, hallucinations, and delusions, alone or in combination. This revie...
Caroline Kruse, Daniel Weintraub, John E. Duda et al.· Neurological Therapeutics· 0 citations
Tuberous sclerosis complex-associated neuropsychiatric disorders (TAND) affect up to 90% of individuals with tuberous sclerosis complex and are a major contributor to reduced quality of life, yet they remain widely under-recognized and undertreated. This narrative review describes how the field evolved from scattered b...
J. Yeom, Young-Soo Kim· Annals of Child Neurology· 0 citations
The case illustrates how an anticholinergic prescribed decades earlier for drug-induced parkinsonism may persist unexamined into a period when the parkinsonian syndrome is more plausibly vascular, at measurable cognitive cost.
D. Vieru, Bogdan Gireadă, Iulia Barticel· Bulletin of Integrative Psyc...· 0 citations
Depression is a frequent comorbidity in Multiple Sclerosis (MS), significantly affecting cases’ quality of life and adherence to treatment. Relapsing-Remitting MS (RRMS), the most prevalent subtype of MS, is notably linked to psychiatric symptoms and impaired functioning resulting from physical disability. This study a...
Raghdaa Abdel Khalek Abdel Halem, M. Dahroug, Mohamed M. el-Hamady et al.· The Egyptian Journal of Neur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.